Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F3 | P13726 | 3/20 | 0.64 |
| ▸ | MAPT | P10636 | 3/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | THRB | P10828 | 1/20 | 0.62 |
| ▸ | ATM | Q13315 | 1/20 | 0.62 |
| ▸ | ESR1 | P03372 | 1/20 | 0.60 |
| ▸ | GSK3B | P49841 | 2/20 | 0.60 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.58 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.58 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.58 |
| ▸ | BACE1 | P56817 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.54 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.54 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2561337 | 1.00 | F3 (0.64) | F3MAPTMEN1KMT2ATHRB | |
| Acrylic Acid SCHEMBL28155059 | 0.91 | THRB (0.60) | F3MAPTMEN1KMT2ATHRB | |
| SCHEMBL13845314 | 0.89 | CA12 (0.53) | F3MAPTMEN1KMT2ATHRB | |
| SCHEMBL4055672 | 0.89 | CA12 (0.53) | F3MAPTMEN1KMT2ATHRB | |
| SCHEMBL4055668 | 0.89 | CA12 (0.53) | F3MAPTMEN1KMT2ATHRB | |
| SCHEMBL1399888 | 0.88 | ESR1 (0.59) | F3MAPTMEN1KMT2ATHRB | |
| SCHEMBL4548370 | 0.88 | ESR1 (0.59) | F3MAPTMEN1KMT2ATHRB | |
| SCHEMBL19244300 | 0.87 | ESR1 (0.51) | F3MAPTMEN1KMT2ATHRB | |
| SCHEMBL19244302 | 0.87 | ESR1 (0.51) | F3MAPTMEN1KMT2ATHRB | |
| SCHEMBL10079597 | 0.85 | KMT2A (0.52) | F3MAPTMEN1KMT2ATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101194878-B | Compressed powder composition | OREAL | 2012-10-31 | — | — | CN | claimed |
| EP-3208301-B1 | RESIN COMPOSITION AND OPTICAL COMPENSATION FILM USING SAME | TOSOH CORP (JP) | 2019-04-03 | — | — | EP | disclosed |
| US-10126478-B2 | Resin composition and optical compensation film using same | TOSOH CORPORATION (JP) | 2018-11-13 | — | — | US | disclosed |
| US-20170242174-A1 | RESIN COMPOSITION AND OPTICAL COMPENSATION FILM USING SAME | TOSOH CORPORATION (JP) | 2017-08-24 | — | — | US | disclosed |
| EP-3208301-A1 | RESIN COMPOSITION AND OPTICAL COMPENSATION FILM USING SAME | Tosoh Corporation (JP) | 2017-08-23 | — | — | EP | disclosed |
| US-20130053566-A1 | CATIONIC PALLADIUM COMPLEXES COMPRISING DIAMINO CARBENE LIGANDS AND THEIR USE IN CATALYSIS | KANATA CHEMICAL TECHNOLOGIES INC. (CA) | 2013-02-28 | — | — | US | disclosed |
| CN-101194878-B | Compressed powder composition | OREAL | 2012-10-31 | — | — | CN | disclosed |
| WO-2011127579-A1 | CATIONIC PALLADIUM COMPLEXES COMPRISING DIAMINO CARBENE LIGANDS AND THEIR USE IN CATALYSIS | KANATA CHEMICAL TECHNOLOGIES INC. (CA) | 2011-10-20 | — | — | WO | disclosed |
| CN-101194878-A | Compressed powder composition | OREAL (FR) | 2008-06-11 | — | — | CN | disclosed |
| EP-1368287-B1 | PROCESS FOR A HOMOGENEOUSLY CATALYZED C-C COUPLING REACTION | DSM IP ASSETS BV (NL) | 2008-03-26 | — | — | EP | disclosed |
| US-6342627-B1 | ESTER INTERCHANGE WITH ALCOHOL IN THE PRESENCE OF LANTHANOIDE METAL ALKOXIDE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053566-A1 | CATIONIC PALLADIUM COMPLEXES COMPRISING DIAMINO CARBENE LIGANDS AND THEIR USE IN CATALYSIS | MLX, LBR, LRRK2 | F3 1741/4885MAPT 4116/4885MEN1 2931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.